Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1987 Sep;92(1):181-7.
doi: 10.1111/j.1476-5381.1987.tb11310.x.

Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets

M W Radomski  1 , R M Palmer, S Moncada
Affiliations
Comparative Study

Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets

M W Radomski et al. Br J Pharmacol. 1987 Sep.

Abstract

1 The pharmacological effects of endothelium-derived relaxing factor (EDRF), nitric oxide (NO) and prostacyclin on human and rabbit platelets were examined. 2 EDRF is released from porcine aortic endothelial cells, cultured on microcarriers and treated with indomethacin, in sufficient quantities to inhibit platelet aggregation induced by 9,11-dideoxy-9 alpha, 11 alpha-methano epoxy-prostaglandin F2 alpha (U46619) and collagen. 3 The anti-aggregating activity of EDRF was potentiated by M&B 22948, a selective inhibitor of cyclic GMP phosphodiesterase, and by superoxide dismutase (SOD) and was inhibited by haemoglobin and Fe2+. 4 Both NO and prostacyclin inhibited platelet aggregation. 5 The anti-aggregatory activity of NO, but not that of prostacyclin, was potentiated by M&B 22948 and by SOD and was inhibited by haemoglobin and Fe2+. Thus NO is a potent inhibitor of platelet aggregation whose activity on platelets mimics that of EDRF. 6 It is likely that the inhibitory effect of NO on platelets represents the action of endogenous EDRF and therefore this substance, together with prostacyclin, is a regulator of platelet-vessel wall interactions.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Clin Invest. 1977 Jan;59(1):149-58 - PubMed
    1. J Physiol. 1963 Aug;168:178-95 - PubMed
    1. Prostaglandins. 1977 Mar;13(3):389-97 - PubMed
    1. Biochim Biophys Acta. 1977 May 2;466(3):429-40 - PubMed
    1. Prostaglandins. 1978 Mar;15(3):383-97 - PubMed

Publication types

MeSH terms

LinkOut - more resources

-